NASDAQ · Medical - Devices

AEMD (AEMD) Stock

$0.57 +6.51% NASDAQ: AEMD Healthcare

Valuation

MetricValue
Price$0.57
Market Cap$430885
P/E Ratio-0.02
P/B Ratio0.32
P/S Ratio0.00
EPS (TTM)$-85.80
52-Week High$27.40
52-Week Low$0.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-260.00%
ROA-185.71%
ROCE-180.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.06
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$1.0M$0$0
Operating Profit$-8.0M$-10.0M$-12.0M$-13.0M$-9.0M
Net Profit$-8.0M$-10.0M$-12.0M$-12.0M$-13.0M
EPS$-65.20$-70.60$-58.60$-48.60$-85.80
Op Margin-1197.3%-3542.5%-2072.1%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$19.0M$18.0M$8.0M$7.0M
Total Liabilities$1.0M$2.0M$2.0M$2.0M$2.0M
Cash$10.0M$17.0M$15.0M$5.0M$6.0M
Borrowings$0$1.0M$1.0M$1.0M$1.0M

Latest News

Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream GlobeNewswire · Jul 15, 2026 Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier® PR Newswire · Jul 13, 2026 Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules PR Newswire · Jul 6, 2026 Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier® PR Newswire · Jun 26, 2026 Aethlon Medical advances Hemopurifier study as final trial cohort nears completion Proactive · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-10.0M$-11.0M$-10.0M$-8.0M
Investing Cash Flow$0$-1.0M$-2.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$4.0M
Net Cash Flow$0$7.0M$-3.0M$-9.0M$0
Free Cash Flow$-7.0M$-10.0M$-11.0M$-10.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-109156.33%
Quick Ratio5.68
Interest Coverage—
Return 1Y-94.27%
Return 3Y-99.80%
Return 5Y-99.98%

Ownership

Insiders Held5.15%
Institutions Held5.82%
Institutions Float Held6.13%
Institutional HolderSharesReport Date
Geode Capital Management, LLC24,3642026-03-31
Ikarian Capital, LLC14,3642026-03-31
Shay Capital LLC14,1242026-03-31
Xtx Topco Ltd13,3422026-03-31
Morgan Stanley2,0472026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ALURAllurion Technologies Inc. $4.72 -14.27% -0.08 $4.72M 0.00%
CODX $2.04 -2.86% -0.11 $2.28M 0.00%
ERNA $3.35 -3.46% 0.01 $1.05M 0.00%
IINNInspira Technologies OXY B.H.N. Ltd. $1.26 -5.97% -2.80 $30.34M 0.00%

About AEMD

AEMD is led by CEO James Frakes, employs 14 people, headquartered in US, publicly traded since 1999.

AEMD stock trades at $0.57 with a market capitalization of $430885. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.32, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.56 and $27.40, and currently trades 97.9% below its 52-week high.

On profitability, AEMD generates a return on equity (ROE) of -260.00%, return on capital employed of -180.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides